CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. (CASIF): 2 pipeline candidates · ~1 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.2 months
D/E -1.69 · 0% dilution
Lead: Phase 1/Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for CASI Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.0M
Cash
$5.6M
Quarterly Burn
$20.8M
Runway
1.2 mo
Revenue
$20.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$25
| Holder | Shares | Value |
|---|---|---|
| simplex trading, llc | 228 | $25 |
Frequently asked questions
How many drug candidates are in CASI Pharmaceuticals, Inc.'s pipeline?
CASI Pharmaceuticals, Inc. (CASIF) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CASI Pharmaceuticals, Inc.'s lead drug candidate?
CASI Pharmaceuticals, Inc.'s most advanced tracked candidate is cid-103 (Phase 1/Phase 2) for Chronic Immune Thrombocytopenia; Antibody Mediated Rejection.
What is CASI Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CASI Pharmaceuticals, Inc. has approximately 1.2 months of cash runway.
What is CASI Pharmaceuticals, Inc.'s market capitalization?
CASI Pharmaceuticals, Inc.'s market capitalization is approximately $3.0M.
Get the full picture on CASI Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.